220 related articles for article (PubMed ID: 19217520)
21. Treatment of hyperlipidemia in HIV-infected patients.
Geletko SM; ZuWallack AR
Am J Health Syst Pharm; 2001 Apr; 58(7):607-14. PubMed ID: 11296612
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
[TBL] [Abstract][Full Text] [Related]
23. Management of lipid disorders in patients living with HIV.
Myerson M; Malvestutto C; Aberg JA
J Clin Pharmacol; 2015 Sep; 55(9):957-74. PubMed ID: 25651539
[TBL] [Abstract][Full Text] [Related]
24. [Cardiovascular risk in HIV infected patients].
Raimundo P; Miranda A; Ribeiro J; Mansinho K
Acta Med Port; 2010; 23(4):669-76. PubMed ID: 20687996
[TBL] [Abstract][Full Text] [Related]
25. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
Leonard EG; McComsey GA
Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
[TBL] [Abstract][Full Text] [Related]
26. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.
Calza L; Colangeli V; Manfredi R; Bon I; Re MC; Viale P
J Antimicrob Chemother; 2016 Jun; 71(6):1451-65. PubMed ID: 26846208
[TBL] [Abstract][Full Text] [Related]
27. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
28. [Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience].
Bottaro EG; Caravello O; Scapellato PG; Stambulian M; Vidal GI; Loggia V; Scapellato JL; Thompson F; Cassetti I
Enferm Infecc Microbiol Clin; 2008; 26(6):325-9. PubMed ID: 18588813
[TBL] [Abstract][Full Text] [Related]
29. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial.
Lazzaretti RK; Kuhmmer R; Sprinz E; Polanczyk CA; Ribeiro JP
J Am Coll Cardiol; 2012 Mar; 59(11):979-88. PubMed ID: 22402068
[TBL] [Abstract][Full Text] [Related]
30. Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals.
Calmy A; Montecucco F; James RW
Curr Vasc Pharmacol; 2015; 13(2):167-72. PubMed ID: 24188489
[TBL] [Abstract][Full Text] [Related]
31. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
[TBL] [Abstract][Full Text] [Related]
32. Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.
Gebhardt A; Fichtenbaum CJ
Expert Opin Pharmacother; 2019 Oct; 20(14):1719-1729. PubMed ID: 31232617
[No Abstract] [Full Text] [Related]
33. [Lipid disorders in patients with HIV-induced diseases].
Chanu B; Valensi P
Presse Med; 2005 Sep; 34(15):1087-94. PubMed ID: 16334888
[TBL] [Abstract][Full Text] [Related]
34. The role of statins in the setting of HIV infection.
Eckard AR; McComsey GA
Curr HIV/AIDS Rep; 2015 Sep; 12(3):305-12. PubMed ID: 26126687
[TBL] [Abstract][Full Text] [Related]
35. Management of dyslipidemia in patients with human immunodeficiency virus.
Shalit P
Rev Cardiovasc Med; 2014; 15 Suppl 1():S38-46. PubMed ID: 24987862
[TBL] [Abstract][Full Text] [Related]
36. Treatment of dyslipidemia in HIV-infected patients.
Sekhar RV; Balasubramanyam A
Expert Opin Pharmacother; 2010 Aug; 11(11):1845-54. PubMed ID: 20486828
[TBL] [Abstract][Full Text] [Related]
37. Management of dyslipidemia in patients with HIV disease.
Manfredi R
Clin Microbiol Infect; 2000 Nov; 6(11):579-84. PubMed ID: 11168060
[TBL] [Abstract][Full Text] [Related]
38. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.
Calza L; Manfredi R; Chiodo F
Infection; 2002 Jan; 30(1):26-31. PubMed ID: 11876511
[TBL] [Abstract][Full Text] [Related]
39. Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.
Tarr PE; Rotger M; Telenti A
Pharmacogenomics; 2010 Apr; 11(4):587-94. PubMed ID: 20350140
[TBL] [Abstract][Full Text] [Related]
40. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
Rotger M; Bayard C; Taffé P; Martinez R; Cavassini M; Bernasconi E; Battegay M; Hirschel B; Furrer H; Witteck A; Weber R; Ledergerber B; Telenti A; Tarr PE;
Circ Cardiovasc Genet; 2009 Dec; 2(6):621-8. PubMed ID: 20031643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
